



Testing will be performed at a Labcorp laboratory, including formerly branded Dianon Pathology.

Dianon Systems, Inc.  
1 Forest Parkway  
Shelton, CT 06484  
203-926-7100  
800-328-2666  
dianon.labcorp.com

CONSECUTIVE  
BARCODE

BXXXXXX

# BREAST PATHOLOGY

Direction of Feed  
↑ thru customer's ↑  
printer

## CLIENT INFORMATION

ORDERING PHYSICIAN	NPI#
REFERRING PHYSICIAN	Fax copy of report to: (____)____-____

## CLINICAL/SPECIMEN INFORMATION

Collection Date: \_\_\_\_\_ Time:  A.M.  P.M. No. of Jars \_\_\_\_\_

Fixative:  10% Neutral Buffered Formalin  Other (Specify): \_\_\_\_\_

Time to Fixation (Cold Ischemic Time): \_\_\_\_\_ (minutes/seconds)

MRI  Ultrasound  Stereotactic

Previous Cancer and/or any other relevant Case History:

Narrative Diagnosis/Clinical Data/Signs & Symptoms:

## PATIENT INFORMATION

Name (LAST, FIRST, MIDDLE) \_\_\_\_\_

Address \_\_\_\_\_

City, State, Zip \_\_\_\_\_

Date of Birth: \_\_\_\_\_ Sex:  M  F

Phone Number \_\_\_\_\_ Race: \_\_\_\_\_

MRN / PATIENT ID# \_\_\_\_\_ Chart# \_\_\_\_\_

## BILLING INFORMATION (face sheet & front and back of insurance card must be attached)

Bill:  My Account  Insurance  Medicare  Medicaid  Patient  Workers Comp

Patient Hospital Status:  Inpatient  Outpatient  Non-patient

Insurance Information:  See attached

Insured Information: Name \_\_\_\_\_  
Relationship to Patient (circle one) Self Spouse Child Other \_\_\_\_\_

Primary Insurance Co: \_\_\_\_\_ Authorization # \_\_\_\_\_

Billing Address \_\_\_\_\_ Insured # \_\_\_\_\_

Billing City, State, Zip \_\_\_\_\_ Group # \_\_\_\_\_

Secondary Insurance Co: \_\_\_\_\_ Authorization # \_\_\_\_\_

Billing Address \_\_\_\_\_ Insured # \_\_\_\_\_

Billing City, State, Zip \_\_\_\_\_ Group # \_\_\_\_\_

## SPECIMEN TYPE/INFORMATION

Palpable  Non-palpable #1 Clock Face \_\_\_\_\_ Distance \_\_\_\_\_

Suspicious  Non-suspicious #2 Clock Face \_\_\_\_\_ Distance \_\_\_\_\_

Family History  Microcalcifications #3 Clock Face \_\_\_\_\_ Distance \_\_\_\_\_

#4 Clock Face \_\_\_\_\_ Distance \_\_\_\_\_

### Collection Method

Core Needle  Incisional  Excisional/Lumpectomy  Nipple Smear

Vacuum-Assisted  Sentinel Node  Fine Needle Aspiration  Lymph Node

### Body Site/Location

Left  Right  Upper  Lower

Inner  Outer  Central Portion  Nipple/Areola

Axillary Tail  Other: \_\_\_\_\_

Paraffin Block Site: \_\_\_\_\_ Number of blocks: \_\_\_\_\_

## Physician/Authorized Signature

© 2023 Laboratory Corporation of America® Holdings. All rights reserved.

Patient, Client and Billing information is requested for timely processing of this case. Medicare and other third party payors require that services be medically necessary for coverage, and generally do not cover routine screening tests.

Refer to policies published by your Medicare Administrative Contractor (MAC), CMS, or www.Labcorp.com/MedicareMedicalNecessity when ordering tests that are subject to ABN guidelines.

### Symbols Legend

@ = Subject to Medicare medical necessity guidelines.  
% = Subject to Medicare frequency guidelines.  
# = Medicare deems investigational. Medicare does not pay for services it deems investigational.

## SPECIMEN LABEL INSTRUCTIONS:

- 1.) Complete the requisition with all requested information.
- 2.) Remove the required number of labels from the front of this sheet.
- 3.) Place one (1) label on each specimen container (not on the lid).

PLEASE DISPOSE OF UNUSED LABELS.

All diagnoses should be provided by the ordering physician or his or her authorized designee. Diagnosis/Signs/Symptoms in ICD-CM format in effect at Date of Service (Highest Specificity Required)

ICD-CM	ICD-CM	ICD-CM	ICD-CM
--------	--------	--------	--------

## HISTOLOGY (Gross and Microscopic Exam)

- Breast Histology
- Breast Histology; if malignant reflex to ER, PR, HER2 by IHC; reflex to HER2/CEP17 FISH if 2+ by IHC<sup>+</sup>

Separately billable stains may be added by pathologist when medically necessary to render a diagnosis.

## PROGNOSTIC TISSUE TESTING (Malignant samples only)

- ER, PR, HER2 by IHC, reflex to HER2/CEP17 FISH if 2+ by IHC<sup>+</sup>
- ER/PR (Estrogen Receptor/Progesterone Receptor) by IHC
- Ki-67 by IHC
- PIK3CA Mutation Analysis, Breast Cancer, IVD
- Prosigna<sup>®</sup> Breast Cancer Prognostic Gene Signature Assay@
- Required:** Gross Tumor Size  ≤ 2 cm  > 2 cm
- Required:** Nodal Status  Negative  1-3 Nodes

Other: \_\_\_\_\_

## HER2 TISSUE ANALYSIS<sup>+</sup>

- HER2 by IHC, reflex to HER2/CEP17 FISH if 2+ by IHC
- HER2/CEP17 FISH

## CYTOLOGY

- FNA Site: \_\_\_\_\_  Fluids Type: \_\_\_\_\_
- Other: \_\_\_\_\_

When ordering tests for which Medicare or Medicaid reimbursements will be sought, physicians should order only those tests that are medically necessary for the diagnosis or treatment of the patient.

Dianon Systems, Inc. is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp. 1437 REV 10/20/2023 CL 0356

(PERF)

Name: \_\_\_\_\_

CONSECUTIVE  
BARCODE  
BXXXXXX

Name: \_\_\_\_\_

CONSECUTIVE  
BARCODE  
BXXXXXX

Name: \_\_\_\_\_

CONSECUTIVE  
BARCODE  
BXXXXXX

Name: \_\_\_\_\_

CONSECUTIVE  
BARCODE  
BXXXXXX

Direction of Feed  
↑ thru customer's printer ↑

## Test Combination/Panel Policy

Labcorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the Labcorp request form. Labcorp encourages clients to contact their local Labcorp representative or Labcorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.



In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all Labcorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. Labcorp will process the specimen for a Microbiology test based on source.

ER/PR (Estrogen Receptor/Progesterone Receptor) by IHC	88360x2
Ki-67 by IHC	88360
HER2 by IHC	88360
HER2/CEP17 by FISH	88377
PIK3CA Mutation Analysis, Breast Cancer, IVD	0155U, 88381
Prosigna® Breast Cancer Prognostic Gene Signature Assay	81520, 88381

✦ Wolff, Antonio C. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *J Clin Oncol* 36:2105-2122. 2018 PMID:29846122

Prosigna® is a registered trademark of NanoString Technologies, Inc.

# labcorp

1437 Rev 10/20/2023

LABEL LINER AREA

(PERF)